Department of Vascular Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China.
Department of Neurosurgery, Renmin Hospital of Wuhan University, 99 Zhang Zhidong Rd, Wuhan, 430060, Hubei Province, China.
Curr Atheroscler Rep. 2020 Oct 16;22(12):77. doi: 10.1007/s11883-020-00892-2.
This review focuses on recent evidence examining the role gut microbiota play in coronary heart disease. It also provides a succinct overview of current and future therapies targeting the gut microbiota for coronary heart disease risk reduction.
A consensus has been reached that differences exist in the gut microbiotas of patients with coronary heart disease. Studies have shown that the gut microbiota is associated with obesity, diabetes, dyslipidemia, and hypertension, which are risk factors for coronary heart disease. The gut microbiota is involved in mediating basic metabolic processes, such as cholesterol metabolism, uric acid metabolism, oxidative stress, and inflammatory reactions, through its metabolites, which can induce the development of atherosclerosis and coronary heart disease. Interfering with the composition of gut microbiota, supplementing probiotics, and fecal donation are active areas of research to potentially prevent and treat coronary heart disease. Gut microbiota are causally associated with coronary heart disease. We analyzed the gut microbiota's effects on risk factors for coronary heart disease and studied the effects of gut microbiota metabolites on coronary heart disease. Gut microbiota is a potential target for preventing and treating coronary heart disease.
本综述重点关注肠道微生物群在冠心病中作用的最新证据。 它还简要概述了针对肠道微生物群降低冠心病风险的当前和未来治疗方法。
人们已经达成共识,即冠心病患者的肠道微生物群存在差异。 研究表明,肠道微生物群与肥胖症、糖尿病、血脂异常和高血压有关,这些都是冠心病的危险因素。 肠道微生物群通过其代谢物参与调节胆固醇代谢、尿酸代谢、氧化应激和炎症反应等基本代谢过程,这可能会导致动脉粥样硬化和冠心病的发展。 干预肠道微生物群的组成、补充益生菌和粪便捐赠是预防和治疗冠心病的活跃研究领域。 肠道微生物群与冠心病有因果关系。 我们分析了肠道微生物群对冠心病危险因素的影响,并研究了肠道微生物群代谢物对冠心病的影响。 肠道微生物群是预防和治疗冠心病的潜在靶点。